Navigation Links
Biosimilar Monoclonal Antibodies in Oncology Will Approach Blockbuster Status by 2017

Opportunity for Biosimilars Varies Significantly by Therapeutic Area,

According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake of biosimilar monoclonal antibodies (MAbs) in oncology will drive robust sales of drugs within this class. The most notable near-term biosimilar targets for MAbs in oncology are Genentech/Roche's Herceptin and Rituxan/MabThera.

The new special report Biosimilars 2007-2017: Shifting Payer and Physician Opinion Increases the Hurdles to Uptake forecasts that sales of biosimilar Herceptin will approach blockbuster status in 2017 in Europe alone, and biosimilar Rituxan/MabThera will garner $940 million in sales by 2017 in the United States, France, Germany, Italy, Spain and the United Kingdom. Based on the success of branded Herceptin and Rituxan/MabThera, near-term opportunity exists for drug manufacturers investing in the development of biosimilar MAbs in oncology. The report finds that oncologists will be among the most aggressive users of biosimilar drugs, and the high turnover of oncology patients will accelerate growth and penetration within the relatively un-crowded biosimilar MAb market.

Although oncology will prove to be a robust market, the opportunity for biosimilars varies significantly by therapeutic area, according to the report. For example, owing to an increasingly cautious attitude among neurologists regarding safety and efficacy associated with the use of biosimilars in chronic diseases like multiple sclerosis, the expectations for biosimilar interferon-betas in neurology remain tempered. Additionally, the emergence of novel multiple sclerosis therapies will constrain interferon-beta use over the long-term; prior to biosimilar entry, forecasted sales of interferon-betas in the United States and European Union will fall to $2.3 billion in 2017-a significant decline from their peak sales of more than $4.7 billion in 2010.

"Despite the success of biosimilars in some areas such as cancer treatment, the launches of biosimilar interferon-betas for neurology in Europe in 2010 and in the U.S. in 2014, will not generate significant uptake of these agents," said Nicole Westphal, Ph.D., analyst at Decision Resources. "Given the high cost of clinical development, the conservative prescribing habits of neurologists, and the declining use of interferon-betas by 2017, biosimilar developers may want to explore other classes of biologics in which to invest their research and development funds."

About the Report

Biosimilars 2007-2017: Shifting Payer and Physician Opinion Increases the Hurdles to Uptake covers 18 key biologic brands from seven biologic classes and includes surveys of 402 U.S. and European physicians and 40 MCO pharmacy directors.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.

Christopher Comfort Elizabeth Marshall

781-296-2597 781-296-2563

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
2. The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016
3. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
4. Monoclonal antibody Hb3: A marker for colon cancer progression or as a therapeutic target?
5. Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
6. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
7. Study Shows Mothers Who Take Chlorella Boost Babies Antibodies During Breast Feeding
8. Researchers Develop Quick Way to Create Human Antibodies
9. Anti-HAV antibodies in beta-thalassemia
10. Vegan diet promotes atheroprotective antibodies in patients with rheumatoid arthritis
11. Autoantibodies and neuropsychiatric events in lupus
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a ... number even greater among Millennials (a whopping one in three aged 18 to 25 ... who are dissatisfied with their ink. In fact, RealSelf , the world’s largest ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch ... product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Building on its ... & Johnson (NYSE: JNJ ) today announced ... Companies to significantly reduce the burden of HIV ... 74 percent of new HIV infections among adolescents ... AIDS Day, these new initiatives include collaborations with ...
(Date:12/1/2015)... 2015 ) ... Equipment and Disposables Market by product, by Animal ... their offering. --> ) has ... and Disposables Market by product, by Animal - ... offering. --> Research and Markets ( ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: